FATE THERAPEUTICS INC Total Long-Term Debt
FATE THERAPEUTICS INC (FATE) had Total Long-Term Debt of $18.48 million as of 2018-12-31, per its 10-K filed 2019-03-05.
Discontinued › Balance Sheet › Liabilities › Long-Term Debt, Unclassified
us-gaap:LongTermDebt · last filed 2019-03-05
- 2018-12-31: Long-term Debt $18.48M.
- 2017-12-31: Long-term Debt $19.32M.
- 2016-12-31: Long-term Debt $12.81M.
- 2015-12-31: Long-term Debt $21.57M.
| Period end | Long-term Debt | Long-term Debt as first filed |
|---|---|---|
| 2018-12-31 | $18.48M 10-K · filed 2019-03-05 | |
| 2017-12-31 | $19.32M 10-K · filed 2018-03-05 | |
| 2016-12-31 | $12.81M 10-K · filed 2017-03-16 | |
| 2015-12-31 | $21.57M 10-K · filed 2016-03-03 | |
| 2015-09-30 | $19.28M 10-Q · filed 2015-11-03 | |
| 2015-06-30 | $19.86M 10-Q · filed 2015-08-05 | |
| 2015-03-31 | $19.83M 10-Q · filed 2015-05-07 | |
| 2014-12-31 | $19.62M 10-Q · filed 2015-11-03 | $19.63M 10-K · filed 2015-03-12 |
| 2013-12-31 | $1.75M 10-K · filed 2015-03-12 | |
| 2013-09-30 | $2.25M 10-Q · filed 2013-11-13 | |
| 2012-12-31 | $3.73M 10-K · filed 2014-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |